About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/19/2021.

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

Clinicaltrials.gov identifier NCT03935932

Recruitment Status Recruiting

First Posted May 2, 2019

Last update posted August 20, 2020

Study Description

Brief summary:

This purpose of this study is to determine whether nasal delivery of heated and humidified air for a period of 4 hours will improve the clearance of mucus from the lungs of patients with chronic obstructive pulmonary disease (COPD). Mucus clearance will be measured using a nuclear medicine imaging procedure called a mucociliary clearance scan. Humidified air (with added oxygen if needed) will be delivered from the Fisher and Paykel myAirvo2 heater/humidifier through an Optiflow nasal cannula.

  • Condition or Disease:COPD
  • Intervention/Treatment: Device: nasal delivery of heated and humidified air
  • Phase: N/A
Detailed Description

Chronic bronchitis is a component of Chronic Obstructive Pulmonary Disease (COPD), along with emphysema. COPD is associated with smoking, exposure to environmental pollutants, or occupational exposures. In the airways mucus acts to trap inhaled toxins or pathogens. In a healthy lung mucus is cleared by mucociliary and cough clearance. Mucociliary clearance involves the synchronous motion of cilia underneath the mucus sheet that lines the airways. This drives the mucus sheet out of the airways (like a conveyer belt) continually clearing particulate and pathogens. In chronic bronchitis, mucus is overproduced due to toxic stimuli. Mucus clearance may also be defective due to airway obstruction and insufficient cough. This results in the accumulation of mucus that contributes to airway obstruction. Therapies for improving mucus clearance may decrease the degree of airway obstruction experienced by COPD patients. Heated, high-flow, humidified air or oxygen may improve mucus clearance by hydrating the mucus in the airways and may also help to increase airway patency. A similar intervention was shown to improve mucus clearance in subjects with bronchiectasis. The investigators have developed nuclear imaging-based methods for measuring mucus clearance from the lungs. These techniques have been applied to evaluate novel therapies for the treatment of cystic fibrosis lung disease. Here the investigators will apply these techniques to determine whether treatment with heated-humidified air will improve mucus clearance in subjects with COPD. Study participation involves 3 visits. Study day 1 includes: 1. A conversation with a physician and completion of informed consent 2. Pulmonary function testing (including albuterol administration) 3. The completion of a series of questionnaires Study days 2 and 3 include: 1. A urine pregnancy test (if applicable) 2. Performance of a Co57 transmission scan 3. The inhalation of a radiopharmaceutical (Technetium-99m sulfur colloid) from a nebulizer 4. Lying flat in a nuclear medicine camera for 90 minutes while scans are collected. 5. Remaining at the test center for a follow up scan approximately 2.5 hours later. This scan will take 10 minutes. 6. Nasal delivery of heated humidified air (with supplemental oxygen if needed) at a rate of 30 liters per minute through a nasal cannula, on one study day. This will be started during the first 10 minutes of the 90 minute scanning period and continued for 4 hours. One the other study day there will be no treatment so that a baseline measurement of mucociliary clearance can be made. The order of the study days will be randomized. Participants will be asked to refrain from using short-acting beta agonist (SABA) medications for 6 hours prior to study days 2 and 3, and long-acting beta agonists (LABA) or long-acting muscarinic antagonists (LAMA) for 24 hours prior to study days 2 and 3.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 12 participants
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Intervention Model Description: Open label, single treatment administration, crossover
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: November 2020
  • Estimated Study Completion Date: December 2020
Arms and interventions
Arm Intervention/treatment
Experimental: baseline followed by intervention
Subjects randomized to perform baseline measurement of clearance on study day 2 and measurement of clearance with nasal delivery of heated and humidified air on day 3
Device: nasal delivery of heated and humidified air
Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
Experimental: intervention followed by baseline
Subjects randomized to perform measurement of clearance with nasal delivery of heated and humidified air on day 2 and baseline measurement of clearance on study day 3
Device: nasal delivery of heated and humidified air
Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
Outcome Measures
  • Primary Outcome Measures: 1. Mucociliary clearance rate - 4 hours [ Time Frame: 0-4 hours ]
    Percentage of radioactivity cleared from the right lung
  • Secondary Outcome Measures: 1. Mucociliary clearance rate - 90 min [ Time Frame: 0-90 minutes ]
    Percentage of radioactivity cleared from the right lung
  • 2. Area Above Retention Curve - 90 min [ Time Frame: 0-90 minutes ]
    Area above the curve of normalized retention of radioactivity vs time from the right lung
Eligibility Criteria
  • Ages Eligible for Study: 40 to 85 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Male or Female 40 to 85 years old

2. Diagnosis of chronic bronchitis

3. Able to regularly produce sputum

4. Clinically stable

5. Current smoker or ex-smoker with a tobacco history of ≥10 pack-years (1 pack year = 20
cigarettes smoked per day for 1 year)

6. History of moderate to very severe COPD with a post-bronchodilator FEV1/FVC20% and ≤70% of predicted normal value at enrollment.

7. CAT score ≥ 10, with questions 1 and 2 responses ≥ 5

Exclusion Criteria:

1. Pregnant or nursing or unwilling to perform pregnancy testing

2. Unwilling or unable to refrain for SABA/LABA use ahead of the study

3. Unable to lie recumbent for 90 min,

4. Clinically important pulmonary disease other than COPD (e.g. active lung infection,
clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis,
hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin
deficiency and primary ciliary dyskinesia) or another diagnosed pulmonary or systemic
disease that is associated with elevated peripheral eosinophil counts (e.g. allergic
bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hyper-eosinophilic
syndrome) and/ or radiological findings suggestive of a respiratory disease other than
COPD that is contributing to the subject's respiratory symptoms.

5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,
hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
hematological, psychiatric, or major physical impairment that is not stable in the
opinion of the Investigator and/or could:

- Affect the safety of the subject throughout the study

- Influence the findings of the study or their interpretation

- Impede the subject's ability to complete the entire duration of study

6. Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for
a COPD exacerbation within 2 weeks prior to enrollment, based on last dose of steroids
or last date of hospitalization whatever occurred later

7. Acute upper or lower respiratory infection within 2 weeks prior to enrollment

8. Supplemental oxygen use at greater than 3 liters/min

Contacts and Locations
Contacts

Contact: Tim Corcoran, Ph.D. 412-692-2210 corcorante@upmc.edu

Locations

United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh

Sponsors and Collaborators

Frank C Sciurba

Fisher and Paykel Healthcare

Investigators

Principal Investigator: Frank C Sciurba, MD University of Pittsburgh

More Information
  • Responsible Party: Frank C Sciurba
  • ClinicalTrials.gov Identifier: NCT03935932 History of Changes
  • Other Study ID Numbers: PRO18110238
  • First Posted: May 2, 2019 Key Record Dates
  • Last Update Posted: August 20, 2020
  • Last Verified: August 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: Yes
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by Frank C Sciurba: Chronic bronchitis COPD